All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment combinations improve outcomes in TP53 mutant AML?
How could new treatment combinations improve outcomes in TP53 mutant AML?
Daver begins by discussing a recent study that analyzed patients on hypomethylating agents (HMA) versus cytarabine based regimens. He highlights that HMA based therapy maintained better response rates regardless of TP53 variant allele frequency, unlike the cytrabine regimen. He goes on to outline further HMA regimens, such as combinations with venetoclax. He then discusses immune therapies such as magrolimab and their outcomes. Finally, he explains the results of the recent study using APR-246 and the promising activity of natural killer (NK) and NK CAR-T cell based therapies.
Correlation of responses to venetoclax combination treatment and AML mutations or BCL-2 expression
Results from an exploratory biomarker analysis from two phase Ib/II studies that examined the combination of venetoclax with HMA or LDAC in older...
ASH 2018 | Venetoclax-based therapies for patients with acute myeloid leukemia who are ineligible for intensive chemotherapy
At the 60th ASH Annual Meeting & Exposition, there were several talks focused on the use of venetoclax in combination with...
Subscribe to get the best content related to AML delivered to your inbox